OBJECTIVES:  Psoriasis is a chronic skin disease of scaling and inflammation, typically characterized by erythematous papules and plaques with a silver scale. In Hungary, approximately 150.000 – 200.000 people are affected. We sought to evaluate the available reimbursed psoriasis treatment options, the economic impact of the disease, and in general we attempted to see beyond the market trends and patients characteristics observed in the analysed dataset. METHODS:  Data were derived from the nationwide dataset of the Hungarian National Health Insurance Fund Administration, the single health care financing agency of Hungary. Data were evaluated according to sex, age, geographical region, type of care and specialty of the prescribing physician. The analysis covers data of all reimbursed pharmaceuticals and other medical services between 1 January 2007 and 31 December 2011.  RESULTS:  The median age was between 51 and 55 years. A bimodal age of onset has been recognised in several large studies, but in this patient cohort people between the ages of 30 and 69 were overrepresented. We found no significant deviation between counties, but there is a clear seasonality in the data.  During each year of the analysed period the number of patients who redeemed at least one reimbursed drug fell short compared to the prevalence based estimates. At any given time close to 80% of the patients did not receive any reimbursed treatment and the number of sold packages continuously decreased over the 5-year period. The introduction of biologic treatments also significantly affected the market. CONCLUSIONS:   To our knowledge, no systematic empirical research exists addressing the question of how psoriasis market changed over the time in Hungary. The data suggest relatively poor adherence to treatment regimens frequently seen and documented in other studies as well.